June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Inhibition of Experimental Choroidal Neovascularization by Telomerase-derived Peptide GV1001
Author Affiliations & Notes
  • Eun Kyoung Lee
    Ophthalmology, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Young Joo Kim
    Ophthalmology, Seoul National University Hospital Biomedical Research Institute, Seoul, Korea (the Republic of)
  • Baek-Lok Oh
    Ophthalmology, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Hyeong Gon Yu
    Ophthalmology, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships Eun Kyoung Lee, None; Young Joo Kim, None; Baek-Lok Oh, None; Hyeong Gon Yu, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2291. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eun Kyoung Lee, Young Joo Kim, Baek-Lok Oh, Hyeong Gon Yu; Inhibition of Experimental Choroidal Neovascularization by Telomerase-derived Peptide GV1001. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2291.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

This study was undertaken to investigate the suppressing effects of a reverse-transcriptase-subunit of telomerase (hTERT) derived peptide, GV1001, on choroidal neovascularization (CNV) in a laser-induced rat model.

 
Methods
 

The CNV was induced by 577 nm diode laser photocoagulation in a total of 52 male Brown Norway rats. GV1001 (0.1-, 1-, or 10 nM) or vehicle was subcutaneously administered beginning 3 days before and once daily after laser photocoagulation. Fourteen days after laser injury, spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA) were performed in vivo to evaluate the thickness and leakage of CNV. Choroidal flat mount and histological analysis were conducted to observe the CNV in vitro.

 
Results
 

The CNV thickness in GV1001-treated rats was significantly lower than in vehicle-treated rats by histological analysis. The CNV thickness was 48.73 ± 9.30 µm in 0.1nM group (P < 0.001), 43.07 ± 10.40 µm in 1nM group (P < 0.001), 51.50 ± 12.74 µm in 10nM group (P = 0.002), and 68.81 ± 23.14 µm in the control group. The proportion of CNV lesions with clinically significant fluorescein leakage were 37.9%, 21.1%, and 21.4% in rats treated with 0.1-, 1-, and 10 nM of GV1001, respectively, which were significantly lower than in control rats (66.1%, P < 0.001) (Figure 1).

 
Conclusions
 

GV1001 suppressed laser-induced CNV formation in rats, especially at 1nM concentration. Further study is needed to identify the mechanism responsible for this CNV inhibitory activity of GV1001.  

 
Figure 1. Fluorescein angiographic images. Early (B, E, H, K) and late (C, F, I, L) phase fluorescein angiographic images taken 14 days after laser injury to induce choroidal neovascularization (CNV). (A, B, C) control group. (D, E, F) GV1001 0.1nM group. (G, H, I) GV1001 1nM group. (J, K, L) GV1001 10nM group.
 
Figure 1. Fluorescein angiographic images. Early (B, E, H, K) and late (C, F, I, L) phase fluorescein angiographic images taken 14 days after laser injury to induce choroidal neovascularization (CNV). (A, B, C) control group. (D, E, F) GV1001 0.1nM group. (G, H, I) GV1001 1nM group. (J, K, L) GV1001 10nM group.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×